Autolus Therapeutics (AUTL) Depreciation & Amortization (CF) (2018 - 2025)

Autolus Therapeutics (AUTL) has 6 years of Depreciation & Amortization (CF) data on file, last reported at $2.1 million in Q4 2025.

• For the quarter ending Q4 2025, Depreciation & Amortization (CF) rose 11.85% year-over-year to $2.1 million; the trailing twelve-month figure through Dec 2025 stood at $8.3 million (up 9.82% YoY), and the FY2025 full-year result was $8.3 million, up 9.82% from the prior year.
• Depreciation & Amortization (CF) for Q4 2025 stood at $2.1 million, up from $2.1 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $2.1 million in Q4 2025 and bottomed at $1.4 million in Q3 2023.
• The 4-year median for Depreciation & Amortization (CF) is $1.9 million (2023), against an average of $1.8 million.
• The widest annual swing landed in 2023, when Depreciation & Amortization (CF) decreased 23.39%; it then soared 40.54% in 2024.
• A 4-year view of Depreciation & Amortization (CF) shows it stood at $1.6 million in 2022, then grew by 7.64% to $1.8 million in 2023, then increased by 7.89% to $1.9 million in 2024, then grew by 11.85% to $2.1 million in 2025.
• The last three Depreciation & Amortization (CF) figures came in at $2.1 million (Q4 2025), $2.1 million (Q3 2025), and $2.1 million (Q2 2025), per Business Quant data.

Peer Comparison